Contribute Try STAT+ Today

The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals (VRTX) is taking place in Australia, where an independent committee recommended that the government not cover a new combination treatment due to the cost and financial implications.

In explaining its decision, the Pharmaceutical Benefits Advisory Committee acknowledged that the medicine, called Trikafta, provided a significant benefit for some patients, especially those with a particular gene mutation. But the PBAC also noted that the cost effectiveness had not been satisfactorily established and deferred recommending coverage while Vertex and the government continue talks. (See page 10).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “Neither of these two commitments have been given to date, of course.”
    May one observe that the last 2 words from this quote change a simple statement of fact into a stinging indictment?

Comments are closed.